Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Trombólise facilitada por ultrassom, dirigida por cateter, em embolia pulmonar de risco intermediário alto (HI-PEITHO)

23 de outubro de 2026 atualizado por: Boston Scientific Corporation

Um estudo randomizado de trombólise guiada por cateter e facilitada por ultrassom versus anticoagulação para embolia pulmonar aguda de alto risco intermediário: o estudo de trombólise de embolia pulmonar de alto risco

There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE.

Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after randomization and have assessments while in the hospital as well as at 7 days, 30 days, 6 months and 12 months after randomization. The study will try to find out if one of these treatments is better than the other at reducing the risk of death and other serious problems.

Visão geral do estudo

Descrição detalhada

This study will assess whether ultrasound-facilitated, catheter-directed thrombolysis and standard anticoagulation are associated with a significant reduction in the composite outcome of pulmonary embolism (PE)-related mortality, cardiorespiratory decompensation or collapse, or nonfatal symptomatic and objectively confirmed recurrence of PE compared to anticoagulation alone within seven days of randomization

The HI-PEITHO study has been designed to address the important gaps in clinical evidence by comparing the clinical benefit of the ultrasound-facilitated local delivery of a low dose thrombolytic agent and anticoagulation with those of anticoagulation alone in patients with intermediate-high risk PE at a higher estimated risk of early decompensation based on clinical parameters at presentation.

This study has a focus on improving the safety of thrombolysis and advancing the concept of intermediate-high risk and the PE severity criteria, to better identify patients who may clinically benefit from thrombolysis.

The results of this study will contribute further evidence to the existing data on the treatment and outcomes of acute, intermediate-high risk PE and provide controlled data related to catheter-based interventions.

Data will be entered by the site into an electronic database. The database will include data checks to compare data entered into the database against predefined rules for ranges and consistency with other data fields in the database.

Site monitoring will take place with source data verification to assess the accuracy and completeness of registry data by comparing the data to medical records and study assessments.

Tipo de estudo

Intervencional

Inscrição (Real)

544

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Aachen, Alemanha
        • Uniklinik Aachen
      • Bielefeld, Alemanha
        • Klinikum Bielefeld
      • Bonn, Alemanha
        • GFO Kliniken Bonn
      • Chemnitz, Alemanha
        • Klinikum Chemnitz
      • Freiburg im Breisgau, Alemanha
        • Universitaetsklinikum Freiburg
      • Immenstädt, Alemanha
        • Klinik Immenstadt
      • Lübeck, Alemanha
        • Universitaetsklinikum Schleswig-Holstein
      • Mainz, Alemanha
        • Johannes Gutenberg Universitaet Mainz
      • Munich, Alemanha
        • Klinikum Rechts der Isar
      • Tübingen, Alemanha
        • Universitaetsklinikum Tuebingen
      • Würzburg, Alemanha
        • Universitaetsklinikum Wuerzburg
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294
        • University of Alabama at Birmingham
    • California
      • Los Angeles, California, Estados Unidos, 90048
        • Cedars - Sinai Medical Center
    • Delaware
      • Newark, Delaware, Estados Unidos, 19718
        • Christiana Hospital
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Emory University Hospital
      • Atlanta, Georgia, Estados Unidos, 30309
        • Piedmont Hospital
      • Augusta, Georgia, Estados Unidos, 30904
        • Augusta University
    • Indiana
      • Merrillville, Indiana, Estados Unidos, 46410
        • Methodist Hospitals
    • Kentucky
      • Lousville, Kentucky, Estados Unidos, 40207
        • Baptist Health East Louisville
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • University of Maryland School of Medicine
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan Hospitals
      • Detroit, Michigan, Estados Unidos, 48202
        • Henry Ford Hospital
    • Mississippi
      • Tupelo, Mississippi, Estados Unidos, 38801
        • North Mississippi Medical Center
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68114
        • Nebraska Methodist Hospital
    • New Hampshire
      • Lebanon, New Hampshire, Estados Unidos, 03756
        • Dartmouth-Hitchcock Medical Center
    • New Jersey
      • Newark, New Jersey, Estados Unidos, 07112
        • Newark Beth Israel Medical Center
    • New York
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center
      • New York, New York, Estados Unidos, 10029
        • Mount Sinai Medical Center
      • New York, New York, Estados Unidos, 10075
        • Lenox Hill Hospital
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • University Hospitals of Cleveland
      • Kettering, Ohio, Estados Unidos, 45429
        • Kettering Health
    • Tennessee
      • Kingsport, Tennessee, Estados Unidos, 37660
        • Wellmont Holston Valley Medical Center
      • Nashville, Tennessee, Estados Unidos, 37232
        • Vanderbilt University Medical Center
    • Texas
      • Austin, Texas, Estados Unidos, 78705
        • Seton Medical Center
      • Houston, Texas, Estados Unidos, 77479
        • Houston Methodist Sugarland Hospital
      • Plano, Texas, Estados Unidos, 75093
        • The Heart Hospital Baylor Plano
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • University of Virginia Medical Center
    • Wisconsin
      • Madison, Wisconsin, Estados Unidos, 53792
        • University of Wisconsin Hospitals
      • Besançon, França
        • CHU de Besancon
      • Nîmes, França
        • CHU (Nimes Cedex)
      • Paris, França
        • Hôpital Européen Georges Pompidou (HEGP)
      • Leiden, Holanda
        • Leiden University Medical Center
      • Nieuwegein, Holanda
        • St. Antonius Ziekenhuis
      • Utrecht, Holanda
        • Universitair Medisch Centrum
      • Dublin, Irlanda
        • Mater Misericordiae University Hospital
      • Galway, Irlanda
        • University Hospital Galway
      • Krakow, Polônia
        • John Paul II Hospital
      • Poznan, Polônia
        • Uniwersytecki Szpital Kliniczny w Poznaniu
      • Warsaw, Polônia
        • Medical University of Warsaw
      • Cardiff, Reino Unido
        • University Hospital of Wales
      • London, Reino Unido
        • The Royal Free Hospital
      • Middlesex, Reino Unido
        • Northwick Park Hospital
      • Basel, Suíça
        • University Hospital Basel
      • Lausanne, Suíça
        • Centre Hospitalier Universitaire Vaudois
      • Zurich, Suíça
        • University Hospital Zurich
      • Innsbruck, Áustria
        • A.o. LKH Univ.-Kliniken Innsbruck
      • Sankt Pölten, Áustria
        • Universitätsklinikum St. Pölten
      • Vienna, Áustria
        • Allgemeines Krankenhaus AKH
      • Vienna, Áustria
        • Austria Klinik Ottakring Vienna

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 80 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age 18-80 years, inclusive

  • Objectively confirmed acute PE, based on computed tomography pulmonary angiography (CTPA) showing a filling defect in at least one main or proximal lobar pulmonary artery

  • Elevated risk of early death/hemodynamic collapse, indicated by at least two of the following new-onset clinical criteria:

    1. ECG-documented tachycardia with heart rate ≥100 beats per minute, not due to hypovolemia, arrhythmia, or sepsis;
    2. SBP ≤ 110 mm Hg for at least 15 minutes;
    3. respiratory rate > 20 x min^-1 or oxygen saturation on pulse oximetry (SpO2) < 90% (or partial arterial oxygen pressure < 60 mmHg) at rest while breathing room air;
  • Right-to-left ventricular (RV/LV) diameter ratio ≥ 1.0 on CTPA

  • Serum troponin I or T levels above the upper limit of normal

  • Signed informed consent

Exclusion Criteria:

  • Hemodynamic instability*, i.e. at least one of the following present:

    1. cardiac arrest or need for cardiopulmonary resuscitation;
    2. need for ECMO, or ECMO initiated before randomization
    3. PE-related shock, defined as: (i) SBP < 90 mmHg, or vasopressors required to achieve SBP ≥ 90 mmHg, despite an adequate volume status; and (ii) end-organ hypoperfusion (altered mental status; oliguria/anuria; increased serum lactate);
    4. isolated persistent hypotension (SBP < 90 mmHg, or a systolic pressure drop by at least 40 mmHg for at least 15 minutes), not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who presented with temporary need for fluid resuscitation and/or low-dose catecholamines may be included, provided that they could be stabilized within 2 hours of admission and maintain SBP of ≥ 90 mmHg and adequate organ perfusion without catecholamine infusion.
  • Need for admission to an intensive care unit for a reason other than the index PE episode. NB: Patients who test positive for SARS-CoV-2 can be enrolled where the investigator believes that the pulmonary embolism is the dominant pathology in the patient's clinical presentation and qualifying cardiorespiratory parameters.

  • Temperature above 39 degrees C / 102.2 degrees F

  • Logistical reasons limiting the rapid availability of interventional procedures to treat acute PE (e.g., during the outbreak of an epidemic)

  • Index PE symptom duration > 14 days

  • Active bleeding

  • History of intracranial or intraocular bleeding at any time

  • Stroke or transient ischemic attack within the past 6 months, or previous stroke at any time if associated with permanent disability

  • Central nervous system neoplasm, or metastatic cancer

  • Major neurologic, ophthalmologic, abdominal, cardiac, thoracic, vascular or orthopedic surgery or trauma (including syncope-associated with head strike or skeletal fracture) within the past 3 weeks

  • Platelet count < 100 x 10^9 x L^-1

  • Patients who have received a once-daily therapeutic dose of LMWH or a therapeutic dose of fondaparinux within 24 hours prior to randomization

  • Patients who have received one of the direct oral anticoagulants apixaban or rivaroxaban within 12 hours prior to randomization

  • Patients who have received one of the direct oral anticoagulants dabigatran or edoxaban for the index PE episode, as these drugs are not approved for patients who have not received heparin for at least 5 days

  • Administration of a thrombolytic agent or a glycoprotein IIb/IIIa receptor antagonist during the current hospital stay and/or within 30 days, for any reason

  • Chronic treatment with antiplatelet agents other than low-dose acetylsalicylic acid or clopidogrel 75 mg once daily (but not both). Dual antiplatelet therapy is excluded.

  • Chronic treatment with a direct oral anticoagulant (apixaban, dabigatran, edoxaban or rivaroxaban)

  • Chronic treatment with a vitamin K antagonist, or known coagulopathy including severe hepatic dysfunction, with an International Normalized Ratio (INR) > 1.5

  • Pregnancy or lactation

  • Previous inclusion in the study

  • Known hypersensitivity to alteplase, LMWH or UFH, or to any of the excipients

  • Life expectancy less than 6 months

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Anticoagulation

Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)

Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)

Outros nomes:
  • heparina, HBPM, HNF, anticoagulante, antiplaquetário
Comparador Ativo: Anticoagulation and EkoSonicTM Endovascular System

Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg]

Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)

Outros nomes:
  • heparina, HBPM, HNF, anticoagulante, antiplaquetário

EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg]

Outros nomes:
  • EKOS, USCDT, CDT, trombólise, fibrinólise

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of Participants With PE-Related Mortality
Prazo: Within seven days of randomization

Death resulting from pulmonary embolism occurring within the assessment period.

Within seven days of randomization
Number of Participants With Recurrent Pulmonary Embolism
Prazo: Within seven days of randomization

Symptomatic, objectively confirmed, nonfatal recurrent pulmonary embolism occurring during the assessment period.

Within seven days of randomization
Number of Participants With Cardiorespiratory Decompensation or Collapse
Prazo: Within seven days of randomization

Cardiorespiratory collapse or decompensation is defined as at least one of the following criteria:

  1. cardiac arrest or need for CPR at any time between randomization and day 7;
  2. signs of shock: new-onset persistent arterial hypotension (systolic blood pressure (SBP) below 90 mmHg or SBP drop by at least 40 mm Hg, over at least 15 minutes and despite an adequate volume status; or need for vasopressors to maintain SBP of at least 90 mmHg), accompanied by end-organ hypoperfusion (altered mental status; oliguria/anuria; or increased serum lactate) at any time between randomization and day 7;
  3. placement on extracorporeal membrane oxygenation (ECMO) at any time between randomization and day 7;
  4. intubation, or initiation of noninvasive mechanical ventilation at any time between randomization and day 7;
  5. National Early Warning Score (NEWS) of 9 or higher, between 24 hours and 7 days after randomization, confirmed on consecutive measurements taken twice, 15 minutes apart.
Within seven days of randomization

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Right Ventricular-to-Left Ventricular (RV-to-LV) Diameter Ratio
Prazo: Baseline and 48 hours after the index procedure

The RV-to-LV diameter ratio was assessed by echocardiography at baseline and 48 hours after the index procedure. The ratio was calculated by dividing the right ventricular diameter by the left ventricular diameter. Change from baseline was defined as the difference between the 48-hour and baseline measurements. Higher RV-to-LV ratios indicate greater right ventricular dilation, whereas lower ratios indicate less right ventricular dilation and improvement in right ventricular size relative to the left ventricle.

Baseline and 48 hours after the index procedure
Number of Participants With Cardiorespiratory Decompensation
Prazo: Within seven days of randomization

The number of participants who experienced cardiorespiratory decompensation within 7 days of randomization. Cardiorespiratory decompensation was defined as the occurrence of any of the following: cardiac arrest or receipt of cardiopulmonary resuscitation (CPR), signs of shock, placement on extracorporeal membrane oxygenation (ECMO), intubation or initiation of non-invasive mechanical ventilation, or a National Early Warning Score (NEWS) of 9 or greater. Participants were counted once if they experienced one or more of these events during the 7-day assessment period.

Within seven days of randomization
Number of Participants With GUSTO Major (Moderate or Severe) Bleeding
Prazo: Within seven days of randomization

Major bleeding will be adjudicated according to the GUSTO criteria:

  1. GUSTO severe or life-threatening bleeding: A bleeding episode that leads to hemodynamic compromise requiring emergency intervention (such as replacement of fluid and/or blood products, inotropic support, or surgical treatment), or is life-threatening or fatal.
  2. GUSTO moderate bleeding (a bleeding episode requiring blood transfusion(s), but which is not deemed life-threatening and does not lead to hemodynamic compromise requiring emergency fluid replacement, inotropic support, or interventional treatment).
Within seven days of randomization
Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding
Prazo: Within 7 days, 30 days, and 6 months of randomization

Major bleeding will also be adjudicated according to the ISTH criteria:

  1. Fatal bleeding and/or
  2. Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome) and/or
  3. Bleeding causing a fall in hemoglobin level of 20 g/L (2 g/dL) or more, or leading to transfusion of two or more units of whole blood or red blood cells.
Within 7 days, 30 days, and 6 months of randomization
Number of Participants With Ischemic or Hemorrhagic Stroke
Prazo: Within 7 days and 30 days following randomization

Occurrence of ischemic or hemorrhagic stroke during the assessment period. Participants were counted once for each assessment time point if an ischemic or hemorrhagic stroke occurred.

Within 7 days and 30 days following randomization
Number of Participants With All-Cause Mortality
Prazo: Within 7 days, 30 days, 6 months, and 12 months of randomization

Death from any cause.

Within 7 days, 30 days, 6 months, and 12 months of randomization
Number of Participants With at Least One Serious Adverse Event
Prazo: Within 30 days of randomization

Number of participants who experienced at least one serious adverse event.

Within 30 days of randomization
Number of Participants With All-Cause Mortality, Cardiorespiratory Collapse or Decompensation, or Recurrent Pulmonary Embolism
Prazo: Within 30 days of randomization

Death due to any cause, Cardiorespiratory collapse or decompensation should fulfill at least one of the following criteria:

  1. cardiac arrest or need for CPR at any time between randomization and day 7;
  2. signs of shock: new-onset persistent arterial hypotension (SBP below 90 mmHg or SBP drop by at least 40 mmHg over at least 15 minutes, and despite an adequate filling status; or need for vasopressors to maintain SBP of at least 90 mmHg), accompanied by end-organ hypoperfusion (altered mental status; oliguria/anuria; or increased serum lactate) at any time between randomization and day 7;
  3. placement on ECMO at any time between randomization and day 7;
  4. intubation, or initiation of non-invasive mechanical ventilation at any time between randomization and day 7;
  5. National Early Warning Score (NEWS) of 9 or higher, between 24 hours and 7 days after randomization, confirmed on consecutive measurements, taken twice.
Within 30 days of randomization
Number of Participants With Symptomatic Recurrent Pulmonary Embolism
Prazo: Within 30 days and 6 months of randomization

Number of participants who experienced symptomatic recurrent pulmonary embolism.

Within 30 days and 6 months of randomization
Change From Baseline in RV Dysfunction on Echocardiography
Prazo: 6 months

Right ventricle to left ventricle end diastolic diameter ratio (RV/LV).

6 months
Duration of Hospitalization for the Index Pulmonary Embolism Event
Prazo: Within 30 days of randomization

Length of hospital stay was calculated as the number of days between hospital admission and hospital discharge.

Within 30 days of randomization
Duration of Stay in the Intensive Care Unit (ICU), Intermediate Care Unit, or Coronary Care Unit for the Index Pulmonary Embolism Event
Prazo: Within 30 days of randomization

Length of stay was calculated as the time between admission to and discharge from the intensive care unit (ICU), intermediate care unit, or coronary care unit during hospitalization.

Within 30 days of randomization
Functional Status as Measured by World Health Organization (WHO) Functional Class
Prazo: Up to 7 days, 30 days, 6 and 12 months of randomization

WHO Functional Class categorizes symptom severity and physical activity limitation. Class I indicates no limitation of physical activity; Class II indicates slight limitation of physical activity; Class III indicates marked limitation of physical activity; and Class IV indicates inability to perform physical activity without symptoms, with symptoms that may be present at rest. Lower classes (I-II) represent better functional status, whereas higher classes (III-IV) represent worse functional status. Participants were classified according to WHO Functional Class at each assessment time point.

Up to 7 days, 30 days, 6 and 12 months of randomization
Functional Status as Measured by 6-Minute Walk Test (6MWT)
Prazo: 30 days, 6 months, and 12 months of randomization

The 6MWT measures the distance a patient can walk on a flat surface in a period of 6 minutes. A 100-meter distance is measured in a hallway, and the patient is asked to walk quickly as many laps as they can over the course of the timed test. Greater distances indicate better functional exercise capacity, whereas shorter distances indicate greater functional limitation. The total distance is measured. The patient's baseline vitals and symptoms are compared to their condition at the completion of the test.

30 days, 6 months, and 12 months of randomization
Functional Status as Measured by Post-Venous Thromboembolism Functional Status (PVFS) Scale
Prazo: 30 days, 6 months, and 12 months of randomization

The Post-Venous Thromboembolism Functional Status (PVFS) Scale assesses functional limitations following a venous thromboembolic event. Participants are classified according to the following grades: Grade 0 = no functional limitations or symptoms; Grade 1 = symptoms present but no limitations in usual activities; Grade 2 = slight functional limitations requiring occasional modification of activities; Grade 3 = moderate functional limitations requiring regular modification of activities; Grade 4 = severe functional limitations with inability to perform usual activities without assistance; Grade 5 = death. Lower grades (0-1) indicate better functional status and less disability, while higher grades (3-4) indicate worse functional status and greater disability. Participants were assessed at each study time point and classified according to the PVFS grade that best described their functional status.

30 days, 6 months, and 12 months of randomization
Quality of Life Using PEmb-QOL
Prazo: 6 and 12 months

PEmb-QOL is a questionnaire that assesses post-pulmonary embolism quality of life in the context of pulmonary-specific symptoms. The PEmb-QOL questionnaire contains six dimensions based on the contents of the items: frequency of complaints, limitations in activities of daily living, work-related problems, social limitations, intensity of complaints and emotional complaints. Higher scores indicate worse outcome.

6 and 12 months
Quality of Life Using SF-36
Prazo: 6 and 12 months

The SF-36 questionnaire is a generic quality of life measure containing eight health domains (physical functioning, physical role, pain, general health, vitality, social function, emotional role functioning, and mental health). The scoring is on a 0-100 scale, with a higher score indicating better health. Scores are combined into two overall summary scores: physical health summary score and mental health summary score.

6 and 12 months
Quality of Life Using EQ-5D Scale
Prazo: 6 and 12 months

The EQ-5D is a patient reported outcome that provides a simple descriptive profile and single index value for health status. The questionnaire consists of 5 questions pertaining to specific health dimensions, including mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health status rating scale.

6 and 12 months
Diagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Prazo: Within 12 months

CTEPH will be diagnosed by the investigational site according to presence of all of the following criteria:

  1. At least one mismatched segmental perfusion defect demonstrated by ventilation/perfusion scanning after 3 months of adequate therapeutic anticoagulation
  2. Resting mean pulmonary arterial pressure (mPAP) ≥25 mmHg measured by invasive right heart catheterization
  3. Pulmonary capillary wedge pressure ≤15 mmHg.
Within 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Stavros Konstantinides, MD, University Medical Center Mainz, Mainz, Germany
  • Investigador principal: Kenneth Rosenfield, MD, Massachusetts General Hospital, Boston, Massachusetts, USA

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

2 de agosto de 2021

Conclusão Primária (Real)

31 de julho de 2025

Conclusão do estudo (Real)

18 de agosto de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

2 de março de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

5 de março de 2021

Primeira postagem (Real)

10 de março de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

23 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever